Biblioteca Humberto Rosselli Quijano
Información del autor
Autor Jeremy D. Coplan |
Documentos disponibles escritos por este autor (3)
Refinar búsquedaEfficacy of open-label nefazodone treatment in patients with panic disorder / Laszlo A. Papp en Journal of Clinical Psychopharmacology, Año 2000 - Vol. 20 - No. 5 (Octubre)
Título : Efficacy of open-label nefazodone treatment in patients with panic disorder Tipo de documento: texto impreso Autores: Laszlo A. Papp, Autor ; Jeremy D. Coplan, Autor ; Jose M. Martínez, Autor Fecha de publicación: 2023 Artículo en la página: pp. 544-546 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antidepresivos de segunda generación, Trastorno de pánico, Piperazinas, Triazoles. Resumen: Fifteen patients with panic disorder participated in a 12-week treatment trial with open-label nefazodone. Nefazodone was well-tolerated with minimal side effects; none of the patients reported sexual dysfunction, and only one patient experienced weight gain. Although the response rate was lower than that found with most other antipanic medications, given its favorable side effect profile, nefazodone may be a good alternative for patients apprehensive about potential adverse drug reactions. Link: ./index.php?lvl=notice_display&id=31169
in Journal of Clinical Psychopharmacology > Año 2000 - Vol. 20 - No. 5 (Octubre) . - pp. 544-546[artículo] Efficacy of open-label nefazodone treatment in patients with panic disorder [texto impreso] / Laszlo A. Papp, Autor ; Jeremy D. Coplan, Autor ; Jose M. Martínez, Autor . - 2023 . - pp. 544-546.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Journal of Clinical Psychopharmacology > Año 2000 - Vol. 20 - No. 5 (Octubre) . - pp. 544-546
Palabras clave: Antidepresivos de segunda generación, Trastorno de pánico, Piperazinas, Triazoles. Resumen: Fifteen patients with panic disorder participated in a 12-week treatment trial with open-label nefazodone. Nefazodone was well-tolerated with minimal side effects; none of the patients reported sexual dysfunction, and only one patient experienced weight gain. Although the response rate was lower than that found with most other antipanic medications, given its favorable side effect profile, nefazodone may be a good alternative for patients apprehensive about potential adverse drug reactions. Link: ./index.php?lvl=notice_display&id=31169
Título : A pilot study of hippocampal volume and N-acetylaspartate (NAA) as response biomarkers in riluzole-treated patients with GAD Tipo de documento: texto impreso Autores: Chadi G. Abdallah, Autor ; Jeremy D. Coplan, Autor ; Andrea Parolin Jackowski, Autor Fecha de publicación: 2021 Artículo en la página: pp. 276-284 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Riluzol, Trastorno de ansiedad generalizada, Biomarcadores, Glutamato, N-acetilaspartato, Volumen del hipocampo, Espectroscopia de resonancia magnética Resumen: Anxiolytic benefit following chronic treatment with the glutamate modulating agent riluzole in patients with generalized anxiety disorder (GAD) was previously associated with differential changes in hippocampal NAA concentrations. Link: ./index.php?lvl=notice_display&id=27081
in European Neuropsychopharmacology > Año 2013 - Vol. 23 - No.4 (Abril) . - pp. 276-284[artículo] A pilot study of hippocampal volume and N-acetylaspartate (NAA) as response biomarkers in riluzole-treated patients with GAD [texto impreso] / Chadi G. Abdallah, Autor ; Jeremy D. Coplan, Autor ; Andrea Parolin Jackowski, Autor . - 2021 . - pp. 276-284.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in European Neuropsychopharmacology > Año 2013 - Vol. 23 - No.4 (Abril) . - pp. 276-284
Palabras clave: Riluzol, Trastorno de ansiedad generalizada, Biomarcadores, Glutamato, N-acetilaspartato, Volumen del hipocampo, Espectroscopia de resonancia magnética Resumen: Anxiolytic benefit following chronic treatment with the glutamate modulating agent riluzole in patients with generalized anxiety disorder (GAD) was previously associated with differential changes in hippocampal NAA concentrations. Link: ./index.php?lvl=notice_display&id=27081
Título : Psychoneuroendocrinology of anxiety disorders Tipo de documento: texto impreso Autores: Gregory M. Sullivan, Autor ; Jeremy D. Coplan, Autor ; Jack M. Gorman, Autor Fecha de publicación: 2020 Artículo en la página: pp. 397-412 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Metabolismo - corteza suprarrenal, Trastornos de ansiedad, Hormona de crecimiento humano, Sistema metabolico pituitario-suprarrenal. Resumen: This article focuses on neuroendocrine measures in anxiety disorders and their relationships to neurotransmitter and neuroendocrine function. In particular, the hypothalamic-pituitary-somatotropin and the hypothalamic-pituitary-adrenal (HPA) axes are emphasized, and a role for extrahypothalamic corticotropin releasing factor is proposed. Link: ./index.php?lvl=notice_display&id=25059
in Psychiatric Clinics of North America > Año 1998- Vol. 21 No. 2 (Junio) . - pp. 397-412[artículo] Psychoneuroendocrinology of anxiety disorders [texto impreso] / Gregory M. Sullivan, Autor ; Jeremy D. Coplan, Autor ; Jack M. Gorman, Autor . - 2020 . - pp. 397-412.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Psychiatric Clinics of North America > Año 1998- Vol. 21 No. 2 (Junio) . - pp. 397-412
Palabras clave: Metabolismo - corteza suprarrenal, Trastornos de ansiedad, Hormona de crecimiento humano, Sistema metabolico pituitario-suprarrenal. Resumen: This article focuses on neuroendocrine measures in anxiety disorders and their relationships to neurotransmitter and neuroendocrine function. In particular, the hypothalamic-pituitary-somatotropin and the hypothalamic-pituitary-adrenal (HPA) axes are emphasized, and a role for extrahypothalamic corticotropin releasing factor is proposed. Link: ./index.php?lvl=notice_display&id=25059
